NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
14/11/2023
Voltar para busca
Dado oficial do USPTO
PALSAR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
65
Atualização mais recente
14/11/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1
Data de depósito
06/09/2019
Data de registro
14/11/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
14/11/2023
Última transação
14/11/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Tokyo, JP
Examinador
HERRERA-MARCUS, ROSELLE MORALDE
Unidade examinadora
N60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
SEKISUI MEDICAL CO., LTD.
Representantes
Boris Umansky LADAS & PARRY LLP
Classificação técnica
Classes Nice
Classe 1
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Nucleic acid sequences as reagents for use in genetic researchother than for medical or veterinary purposes; nucleic acids for scientific purposeschemical compositions and materials in the nature of chemicals for use in genotypingall as chemicals for use in industry; reagentsenzymeschemical compositionschemical primers and chemical probes for use in the manufacture of pharmaceuticals; biochemical reagents commonly known as probesfor detecting and analyzing molecules in protein or nucleotide arrays; nucleic acid sequences known as probes for use in signal amplification for use in the manufacture of diagnostic reagents for scientific or medical research use; nucleic acid sequences known as probes for use in signal amplification techniques for use in the pharmaceutical industry; nucleic acid sequences known as probes for use in detecting nucleic acids for raw material in the manufacture of pharmaceuticals; nucleic acid sequences known as probes for use in detecting mRNA directly without synthesizing cDNA for use as a raw material in the manufacture of diagnostic reagents; nucleic acid sequences known as probes for use in multiplex detection of mRNAs simultaneously in a single tube reaction for use as a raw material in the manufacture of diagnostic reagents for scientific or research use; nucleic acid sequences known as probes for use in forming self-assembly honeycomb structure for use as an ingredient in pharmaceuticals; nucleic acid sequences known as probes for use in quantifying intact drug and parent drug fragment for use as an ingredient in diagnostic reagents; nucleic acid sequences known as probes for use in quantifying intact drug and parent drug fragment at picogram-nanogram levels for an ingredient in diagnostic reagents for scientific or medical research; nucleic acid sequences known as probes for use in quantifying parent and fragments with only 1-2 mers difference for use in industry utilizing technology of DNA self-assembly reactions; nucleic acid sequences known as probes for use in measuring analytes directly from matrix without using highly purified nucleic acid or reverse transcriptase reaction for as diagnostic reagents for scientific or medical research use; nucleic acid sequences known as probes for use in quantifying using samples from bloodtissue and cell lysates for use in cell cultures other than for medical or veterinary use; nucleic acid sequences known as probes for use in simultaneously quantifying heteroduplex oligonucleotide drugs for diagnostic reagents and preparationsexcept for medical or veterinary use; nucleic acid sequences known as probes for use in analyzing samples using bioanalytical methods for use in industry utilizing technology of DNA self-assembly reactions; nucleic acid sequences known as probes for use in self-assembly reactions for as reagents for use in industry utilizing technology of DNA self-assembly reactions; nucleic acid sequences known as probes to be used as signal amplifier for use in industry to detect nucleic acids; nucleic acid sequences known as probes for use in analyzing samples without using PCR for use in industry to detect mRNAs; biochemical reagents commonly known as probes for use in signal amplification for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in signal amplification techniques for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in detecting nucleic acids for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in detecting mRNA directly without synthesizing cDNA for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in multiplex detection of mRNAs simultaneously in a single tube reaction for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in forming self-assembly honeycomb structure for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in quantifying intact drug and parent drug fragment for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in quantifying intact drug and parent drug fragment at picogram-nanogram levels for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in quantifying parent and fragments with only 1-2 mers difference for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in measuring analytes directly from matrix without using highly purified nucleic acid or reverse transcriptase reaction for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in quantifying using samples from bloodtissue and cell lysates for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in simultaneously quantifying heteroduplex oligonucleotide drugs for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in analyzing samples using bioanalytical methods for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in self-assembly reactions for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes to be used as signal amplifier for use in industry utilizing technology of DNA self-assembly reactions; biochemical reagents commonly known as probes for use in analyzing samples without using PCR for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in signal amplification for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in signal amplification techniques for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in detecting nucleic acids for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in detecting mRNA directly without synthesizing cDNA for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in multiplex detection of mRNAs simultaneously in a single tube reaction for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in forming self-assembly honeycomb structure for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in quantifying intact drug and parent drug fragment for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in quantifying intact drug and parent drug fragment at picogram-nanogram levels for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in quantifying parent and fragments with only 1-2 mers difference for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in measuring analytes directly from matrix without using highly purified nucleic acid or reverse transcriptase reaction for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in quantifying using samples from bloodtissue and cell lysates for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in simultaneously quantifying heteroduplex oligonucleotide drugs for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in analyzing samples using bioanalytical methods for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in self-assembly reactions for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes to be used as signal amplifier for use in industry utilizing technology of DNA self-assembly reactions; biotin labeled honeycomb probes for use in analyzing samples without using PCR for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in signal amplification for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in signal amplification techniques for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in detecting nucleic acids for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in detecting mRNA directly without synthesizing cDNA for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in multiplex detection of mRNAs simultaneously in a single tube reaction for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in forming self-assembly honeycomb structure for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in quantifying intact drug and parent drug fragment for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in quantifying intact drug and parent drug fragment at picogram-nanogram levels for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in quantifying parent and fragments with only 1-2 mers difference for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in measuring analytes directly from matrix without using highly purified nucleic acid or reverse transcriptase reaction for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in quantifying using samples from bloodtissue and cell lysates for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in simultaneously quantifying heteroduplex oligonucleotide drugs for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in analyzing samples using bioanalytical methods for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in self-assembly reactions for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled to be used as signal amplifier for use in industry utilizing technology of DNA self-assembly reactions; honeycomb probes to which biotins are labeled for use in analyzing samples without using PCR for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in signal amplification for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in signal amplification techniques for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in detecting nucleic acids for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in detecting mRNA directly without synthesizing cDNA for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in multiplex detection of mRNAs simultaneously in a single tube reaction for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in forming self-assembly honeycomb structure for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in quantifying intact drug and parent drug fragment for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in quantifying intact drug and parent drug fragment at picogram-nanogram levels for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in quantifying parent and fragments with only 1-2 mers difference for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in measuring analytes directly from matrix without using highly purified nucleic acid or reverse transcriptase reaction for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in quantifying using samples from bloodtissue and cell lysates for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in simultaneously quantifying heteroduplex oligonucleotide drugs for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in analyzing samples using bioanalytical methods for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in self-assembly reactions for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair to be used as signal amplifier for use in industry utilizing technology of DNA self-assembly reactions; A short DNA probe pair for use in analyzing samples without using PCR for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in signal amplification for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in signal amplification techniques for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in detecting nucleic acids for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in detecting mRNA directly without synthesizing cDNA for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in multiplex detection of mRNAs simultaneously in a single tube reaction for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in forming self-assembly honeycomb structure for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in quantifying intact drug and parent drug fragment for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in quantifying intact drug and parent drug fragment at picogram-nanogram levels for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in quantifying parent and fragments with only 1-2 mers difference for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in measuring analytes directly from matrix without using highly purified nucleic acid or reverse transcriptase reaction for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in quantifying using samples from bloodtissue and cell lysates for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in simultaneously quantifying heteroduplex oligonucleotide drugs for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in analyzing samples using bioanalytical methods for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in self-assembly reactions for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes to be used as signal amplifier for use in industry utilizing technology of DNA self-assembly reactions; self-assembled DNA probes for use in analyzing samples without using PCR for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in signal amplification for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in signal amplification techniques for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in detecting nucleic acids for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in detecting mRNA directly without synthesizing cDNA for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in multiplex detection of mRNAs simultaneously in a single tube reaction for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in forming self-assembly honeycomb structure for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in quantifying intact drug and parent drug fragment for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in quantifying intact drug and parent drug fragment at picogram-nanogram levels for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in quantifying parent and fragments with only 1-2 mers difference for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in measuring analytes directly from matrix without using highly purified nucleic acid or reverse transcriptase reaction for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in quantifying using samples from bloodtissue and cell lysates for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in simultaneously quantifying heteroduplex oligonucleotide drugs for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in analyzing samples using bioanalytical methods for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in self-assembly reactions for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions to be used as signal amplifier for use in industry utilizing technology of DNA self-assembly reactions; probes made by DNA self-assembly reactions for use in analyzing samples without using PCR for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in signal amplification for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in signal amplification techniques for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in detecting nucleic acids for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in detecting mRNA directly without synthesizing cDNA for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in multiplex detection of mRNAs simultaneously in a single tube reaction for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in forming self-assembly honeycomb structure for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in quantifying intact drug and parent drug fragment for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in quantifying intact drug and parent drug fragment at picogram-nanogram levels for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in quantifying parent and fragments with only 1-2 mers difference for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in measuring analytes directly from matrix without using highly purified nucleic acid or reverse transcriptase reaction for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in quantifying using samples from bloodtissue and cell lysates for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in simultaneously quantifying heteroduplex oligonucleotide drugs for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in analyzing samples using bioanalytical methods for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in self-assembly reactions for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier to be used as signal amplifier for use in industry utilizing technology of DNA self-assembly reactions; A signal amplifier for use in analyzing samples without using PCR for use in industry utilizing technology of DNA self-assembly reactions; self-assembly formed by a short DNA probe pair for use in industry utilizing technology of DNA self-assembly reactions
Publicações
Histórico de despachos e eventos da marca no USPTO.
65 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
14/11/2023
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
12/10/2023
IUCN
NOTICE OF ALLOWANCE CANCELLED
28/08/2023
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
28/08/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
28/02/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/01/2023
PUBO
PUBLISHED FOR OPPOSITION
03/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/12/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/10/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/10/2022
ALIE
ASSIGNED TO LIE
25/10/2022
ALIE
ASSIGNED TO LIE
19/09/2022
ALIE
ASSIGNED TO LIE
14/09/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/09/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
31/03/2022
GNSL
LETTER OF SUSPENSION E-MAILED
31/03/2022
CNSL
SUSPENSION LETTER WRITTEN
31/03/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/03/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/03/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
10/03/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
13/09/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
10/09/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
10/09/2021
CNSI
SUSPENSION INQUIRY WRITTEN
10/09/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/02/2021
GNSL
LETTER OF SUSPENSION E-MAILED
04/02/2021
CNSL
SUSPENSION LETTER WRITTEN
04/02/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
03/02/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/02/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
03/02/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/02/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/08/2020
GNRT
NON-FINAL ACTION E-MAILED
04/08/2020
CNRT
NON-FINAL ACTION WRITTEN
04/08/2020
DPCC
DIVISIONAL PROCESSING COMPLETE
16/07/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
15/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/07/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/07/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/07/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/07/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
24/06/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
24/06/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
24/06/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
24/06/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
24/06/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
24/06/2020
ALIE
ASSIGNED TO LIE
16/06/2020
DRRR
DIVISIONAL REQUEST RECEIVED
08/06/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/06/2020
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
08/06/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
30/01/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
30/01/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
28/01/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
28/01/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/12/2019
GNRT
NON-FINAL ACTION E-MAILED
06/12/2019
CNRT
NON-FINAL ACTION WRITTEN
06/12/2019
DOCK
ASSIGNED TO EXAMINER
23/11/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
23/09/2019
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
11/09/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
11/09/2019
NWAP
NEW APPLICATION ENTERED
10/09/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PALSAR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.